mendments-certified, College of Pathologists-accredited laboratory. Using its services, customers could perform whole-genome sequencing projects (including phasing and long-read sequencing services) and microarray projects (including large-scale genotyping studies and whole-genome association studies). The company also provides noninvasive prenatal testing services through its partner laboratories that direct samples to the company on a test send-out basis in the company’s Clinical Laboratory Improvements Amendments-certified, College of Pathologists-accredited laboratory. Customers The company’s customers include major genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, agrigenomics, commercial molecular diagnostic laboratories, and consumer genomics companies. Marketing and Distribution The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region. In each of these areas, dedicated sales, service, and application-support personnel are expanding and supporting their respective customer bases. In addition, the company sells through life-science distributors in certain markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and South Africa. Sales The company has sales offices located internationally throughout Europe, the Asia-Pacific region, and Brazil. Principal Markets Life Sciences: The company serves applied markets in life sciences, such as agrigenomics, forensic genomics, and transplant biology. In agrigenomics, government and corporate researchers use the company’s sequencing- and array-based tools to explore the genetic and biological basis for productivity and nutritional constitution in crops and livestock. In forensic genomics, major law enforcement agencies use sequencing to investigate criminal cases, as do military and security intelligence agencies. In transplant diagnostics, the company offers a sample-to-answer solution to perform high resolution HLA typing in a single assay, which enables users to determine how closely the tissues of one person match the tissues of another person. Clinical Genomics: The company provides sample-to-answer solutions to its customers in two key areas of translational and clinical genomics, such as reproductive and genetic health, and oncology. Enterprise Informatics: Enterprise informatics solutions increase the utility of genomic data by allowing customers to aggregate, analyze, archive, and share genomic data. Acquisitions In August 2015, the company acquired GenoLogics Life Sciences Software Inc., a developer of laboratory information management systems. Intellectual Property Illumina, 24sure, BaseSpace, BeadArray, BlueFish, BlueFuse, BlueGnome, cBot, CSPro, DASL, DesignStudio, Epicentre, ForenSeq, Genetic Energy, GenomeStudio, GoldenGate, HiScan, HiSeq, HiSeq X, Infinium, iScan, iSelect, MiniSeq, MiSeq, MiSeqDx, MiSeq FGx, NeoPrep, NextBio, Nextera, NextSeq, SeqMonitor, TruGenome, TruSeq, TruSight, Understand Your Genome, UYG, VeraCode, verifi, VeriSeq, the pumpkin orange color, and the Genetic Energy streaming bases design are certain of the company’s trademarks. As of February 1, 2016, the company owned or had exclusive licenses to 577 issued U.S. patents and 406 pending U.S. patent applications, including 34 allowed applications that have not yet issued as patents. The company’s issued patents cover various aspects of its arrays, assays, oligo synthesis, sequencing technology, instruments, digital microfluidics, and chemical-detection technologies; and have terms that expire between 2016 and 2036. Research and Development The company’s research and development expenses were $401.5 million for the year ended January 3, 2016. Government Regulation Certain of the company’s diagnostic products are available through laboratories that are certified under the Clinical Laboratory Improvements Amendments of 1988. Competition The company’s competitors include Affymetrix, Inc.; Agilent Technologies, Inc.; BGI; Pacific Biosciences of Ca
illumina inc (ILMN:NASDAQ GS)
5200 Illumina Way
San Diego, CA 92122
The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create or control the content.
|No competitor information is available for ILMN.|
|View Industry Companies|
Sponsored Financial Commentaries
To contact ILLUMINA INC, please visit www.illumina.com. Company data is provided by Capital IQ. Please use this form to report any data issues.